News

Dr. Trager is a well-established biotechnology leader deeply versed in the development and application of cellular therapies ...
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage ...
Senti Bio (SNTI)sciences announced the appointment of James B. Trager, Ph.D. to its Scientific Advisory Board. Trager formerly served as the ...
SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage ...
Senti Bio (SNTI)sciences is now participating on the Webull Corporate Connect Service platform. Senti Bio’s portal on the Webull CCS aims to ...